(Q44700790)

5 December 2017

Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival (English)

1 reference

5 December 2017

Alexandrakis MG

1

1 reference

5 December 2017

Passam FH

2

1 reference

5 December 2017

Sfiridaki K

3

1 reference

5 December 2017

Moschandrea J

4

1 reference

5 December 2017

Pappa C

5

1 reference

5 December 2017

Liapi D

6

1 reference

5 December 2017

Petreli E

7

1 reference

5 December 2017

Roussou P

8

1 reference

5 December 2017

Kyriakou DS

9

1 reference

5 December 2017

1 March 2004

1 reference

5 December 2017

1 reference

5 December 2017

28

1 reference

5 December 2017

3

1 reference

5 December 2017

259-266

1 reference

Cloning of a new cytokine that induces IFN-gamma production by T cells

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

1 reference

7 January 2021

Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

The role of IL-18 in innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Evidence of IL-18 as a novel angiogenic mediator

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Angiogenesis and angiogenic mediators in haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Enhanced IL-18 expression in common skin tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Interleukin-18 acts as an angiogenesis and tumor suppressor

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900261-3

7 January 2021

10.1016/S0145-2126(03)00261-3

Identifiers

DOI

1 reference

5 December 2017

1 reference